SAMSUNG-ELECTRONICS
22.11.2021 10:02:09 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that five of its memory products achieved global recognition for successfully reducing its carbon emission, while 20 additional memory products received carbon footprint certification. Samsung’s automotive LED packages also had their carbon footprint verification, a first in the industry for automotive LED packages, further expanding Samsung’s portfolio of eco-conscious ‘green chips’.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006067/en/
“It is exciting to see our environmentally sustainable efforts receiving global acknowledgements,” said Seong-dai Jang, Senior Vice President and Head of DS Corporate Sustainability Management Office at Samsung Electronics. “We will continue our path towards a sustainable future with ‘greener’ chips enabled by Samsung’s cutting-edge technology.”
Five memory products achieve the Carbon Trust ‘Reducing CO2’ certification
Five Samsung memory products – HBM2E (8GB), GDDR6 (8Gb), UFS 3.1 (512GB), Portable SSD T7 (1TB), microSD EVO Select (128GB) – recently earned ‘Reducing CO2’ labels from the Carbon Trust. The previous versions of the five products had received the ‘CO2 Measured’ certification from the Carbon Trust last year. The Carbon Trust recently also certified the product carbon footprints of 20 memory products1 by giving them the ‘CO2 Measured’ product carbon footprint label.
The Carbon Trust is an independent and expert partner of organizations that advises businesses on their opportunities in a sustainable, low-carbon world. The Carbon Trust also certifies the environmental footprint of organizations, supply chains and products.
The Reducing CO2 label certifies that a product’s carbon emission has decreased. Samsung was able to cut the carbon emission of the five memory products through enhanced production efficiency. This means that less electricity and raw materials were used per chip. For the Portable SSD T7 (1TB), Samsung used environmentally sustainable paper instead of plastic as packaging material to minimize the carbon footprint of the product.
Samsung estimates that the volume of carbon emissions reduced from the five products, after their release until July 2021, amounts to approximately 680,000 metric tons of CO2, which is equivalent to 11.3 million urban tree seedlings grown for ten years or the greenhouse gas emitted from 149,000 cars driven for one year.
Before a product can be certified for carbon reduction, its current carbon footprint must be validated in order to set the starting line for measuring carbon footprint changes. The CO2 Measured label verifies the current carbon emission of the product with a globally recognized specification (PAS 2050). Thus, the 20 Samsung memory products with the CO2 Measured label has now set the benchmark for future carbon reduction.
“We have certified five of Samsung’s memory chip products with the CO2 Reducing label, and are pleased to bring on board 20 more products with the CO2 Measured label,” said Hugh Jones, Managing Director at the Carbon Trust Advisory. “We hope that Samsung’s efforts could spread out to the entire semiconductor industry, so that the industry can continue its journey towards a more sustainable future.”
Carbon footprint of C-series 3W Automotive LEDs verified by UL
Four C-series 3W Automotive LED packages manufactured by Samsung – Gen3 (third generation) 3W White, Gen3 3W Amber, Gen2 (second generation) 3W White, and Gen2 3W Amber – received verification of their carbon footprint to ISO 14064-3 by UL.
UL, the global safety science leader, provides testing, inspection and certification, advisory and risk management services, decision-making tools, training and business intelligence offerings to help customers based in more than 100 countries solve critical business challenges, achieve sustainability goals, and prepare for future opportunities.
Since Samsung’s C-series 3W Automotive LED packages are energy efficient products that draw less power but produces more light output, they reduce carbon emissions of cars by improving energy efficiency and ensure longer driving range for electric vehicles in a single charge.
“UL congratulates Samsung for pursuing carbon footprint verification for their four C-series 3W Automotive LED packages, which will help automotive manufacturers select products with transparent, verified information about their environmental footprint,” said Doug Lockard, Vice President and General Manager of UL’s Retail and Consumer Products group. “By understanding the carbon impact of products, manufacturers like Samsung can work to reduce those impacts and improve the environmental performance of products over time.”
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
.
1 SODIMM(8GB/16GB), LPDDR5(8GB/12GB/16GB), RDIMM(16GB/32GB), 980 PRO SSD(250GB/500GB/1TB/2TB), HBM2E(16GB), GDDR6(16Gb), UFS 3.1(128GB/256GB), microSD EVO Select(64GB/256GB/512GB), Portable SSD T7(500GB/2TB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
